The Story
Bengaluru-based clinical-stage biotechnology startup Immuneel Therapeutics, co-founded by Biocon founder Kiran Mazumdar-Shaw and Pulitzer-winning oncologist Siddhartha Mukherjee, has successfully raised over ₹100 crore in a fresh Series B funding round. The capital injection witnessed participation from prominent investors including Singularity AMC and Zerodha-backed Rainmatter, alongside continued support from existing institutional backers Eight Roads Ventures and F-Prime Capital. This critical financing will be aggressively deployed to scale the commercialization of Qartemi—India’s first indigenously approved CAR-T therapy for treating Non-Hodgkin Lymphoma and leukemia. Additionally, the proceeds will finance the expansion of Immuneel's localized Good Manufacturing Practice (GMP) facilities and underwrite its strategic market entry into the Asia-Pacific and Middle East corridors.
Why It Matters
The core bottleneck in advanced oncological care globally is extreme pricing rather than scientific limitation. Chimeric Antigen Receptor T-cell (CAR-T) therapy—often referred to as a "living drug"—involves extracting a patient's own immune T-cells, genetically reprogramming them in a laboratory to target specific cancer proteins, and infusing them back into the bloodstream. While highly effective, the prohibitive cost of Western therapies, which routinely range between $350,000 and $700,000 per patient, renders them entirely inaccessible for emerging economies. Immuneel targets this structural friction by building India's first international-standard CAR-T platform. By localizing the highly complex engineering protocols and owning the end-to-end manufacturing pipeline, the startup is successfully delivering global-standard cancer therapies at a fraction of Western costs, fundamentally shifting the unit economics of advanced immunotherapies.
The Strategic Read
This ₹100 crore Series B validates a monumental maturation in India’s deep-tech and biopharma sector. Historically, the Indian pharmaceutical ecosystem has dominated global supply chains through generic drug manufacturing, but it has heavily relied on Western intellectual property for bleeding-edge innovations. Immuneel’s ability to develop, approve, and commercialize a homegrown CAR-T therapy signals that Indian companies can now originate and scale complex genetic therapies domestically. As the company expands into Southeast Asia and the Middle East, it places immense pressure on legacy multinational pharmaceutical giants who have long controlled cell therapy pricing. By establishing a robust, scalable infrastructure for genetically modified therapies, Immuneel not only democratizes survival for millions of patients but also positions India as a dominant structural player in the global future of affordable cell and gene therapy.
For daily, sharp analysis of the biggest moves in the Indian business and startup ecosystem, follow StartupFox.
